Author

Samuel Raimundo Fernandes

TRANSMURAL REMISSION IMPROVES CLINICAL OUTCOMES UP TO 5 YEARS IN PATIENTS WITH CROHN’S DISEASE A MULTICENTER CASE-COHORT STUDY
TRANSMURAL REMISSION IMPROVES CLINICAL OUTCOMES UP TO 5 YEARS IN PATIENTS WITH CROHN’S DISEASE A MULTICENTER CASE-COHORT STUDY

Samuel Raimundo Fernandes  et al.

TRANSMURAL REMISSION IMPROVES CLINICAL OUTCOMES UP TO 5 YEARS IN PATIENTS WITH CROHN’S DISEASE A MULTICENTER CASE-COHORT STUDY
TRANSMURAL REMISSION IMPROVES CLINICAL OUTCOMES UP TO 5 YEARS IN PATIENTS WITH CROHN’S DISEASE A MULTICENTER CASE-COHORT STUDY

MALIGNANT PERITONEAL MESOTHELIOMA IN A YOUNG PATIENT
MALIGNANT PERITONEAL MESOTHELIOMA IN A YOUNG PATIENT

Samuel Raimundo Fernandes  et al.

Transmural remission improves clinical outcomes up to 5 years in Crohn's disease
Transmural remission improves clinical outcomes up to 5 years in Crohn's disease

Samuel Raimundo Fernandes  et al.

PROACTIVE INFLIXIMAB IS MORE EFFECTIVE THAN VEDOLIZUMAB IN INDUCING FECAL CALPROTECTIN REMISSION IN INFLAMMATORY BOWEL DISEASE
PROACTIVE INFLIXIMAB IS MORE EFFECTIVE THAN VEDOLIZUMAB IN INDUCING FECAL CALPROTECTIN REMISSION IN INFLAMMATORY BOWEL DISEASE

Samuel Raimundo Fernandes  et al.

PROPHYLACTIC VERSUS ENDOSCOPY-DRIVEN TREATMENT OF CROHN’S POSTOPERATIVE RECURRENCE: COMPLETED RESULTS OF A RETROSPECTIVE, MULTICENTRIC EUROPEAN STUDY (PORCSE STUDY)
PROPHYLACTIC VERSUS ENDOSCOPY-DRIVEN TREATMENT OF CROHN’S POSTOPERATIVE RECURRENCE: COMPLETED RESULTS OF A RETROSPECTIVE, MULTICENTRIC EUROPEAN STUDY (PORCSE STUDY)

Samuel Raimundo Fernandes  et al.

Item 1 - 6 / 6
1